Loading...
•
Mar 31
AIM ImmunoTech Q1 2025 Earnings Report
AIM ImmunoTech reported a narrower net loss and reduced operating expenses in Q1 2025.
Key Takeaways
AIM ImmunoTech's Q1 2025 results showed a significant reduction in net loss and operating expenses, despite a decline in revenue. The company faces potential delisting from the NYSE American due to non-compliance with stockholders' equity requirements.
Net loss decreased to $3.705 million from $5.817 million year-over-year.
Revenue declined to $16,000 from $40,000 in Q1 2024.
Research and development expenses reduced to $1.08 million from $1.951 million.
General and administrative expenses decreased to $2.545 million from $3.815 million.
AIM ImmunoTech
AIM ImmunoTech
AIM ImmunoTech Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.com Forward Guidance
AIM ImmunoTech is actively pursuing strategies to regain compliance with NYSE American listing requirements and secure additional funding to support its operations.
Positive Outlook
- Net loss reduced significantly year-over-year.
- Decreased R&D and G&A expenses indicate improved cost management.
- Company is exploring various funding sources, including equity offerings.
- Engaged in a forbearance agreement providing temporary financial relief.
- Focused on advancing clinical trials for Ampligen.
Challenges Ahead
- Revenue declined compared to the same quarter last year.
- Cash and cash equivalents decreased, raising liquidity concerns.
- Potential delisting from NYSE American due to non-compliance.
- Working capital deficit indicates short-term financial challenges.
- Stockholders' equity below minimum requirements for continued listing.